Article Versions Notes

Boch C, Reschke M, Igney F, Maier P, Müller P, Danklmaier S, Das K, Hofer T, Wollmann G, Rist W. Evaluating Antibody Pharmacokinetics as Prerequisite for Determining True Efficacy as Shown by Dual Targeting of PD-1 and CD96. Biomedicines. 2022; 10(9):2146. https://doi.org/10.3390/biomedicines10092146

Boch, Christina, Markus Reschke, Frederik Igney, Peter Maier, Philipp Müller, Sarah Danklmaier, Krishna Das, Tamara Hofer, Guido Wollmann, and Wolfgang Rist. 2022. "Evaluating Antibody Pharmacokinetics as Prerequisite for Determining True Efficacy as Shown by Dual Targeting of PD-1 and CD96" Biomedicines 10, no. 9: 2146. https://doi.org/10.3390/biomedicines10092146

Boch, C., Reschke, M., Igney, F., Maier, P., Müller, P., Danklmaier, S., Das, K., Hofer, T., Wollmann, G., & Rist, W. (2022). Evaluating Antibody Pharmacokinetics as Prerequisite for Determining True Efficacy as Shown by Dual Targeting of PD-1 and CD96. Biomedicines, 10(9), 2146. https://doi.org/10.3390/biomedicines10092146